Gotlib J. World Health Organization-defined eosinophilic disorders: 2015 update on diagnosis, risk stratification, and management. Am J Hematol. 2015;90:1077–89.
Gotlib J. World Health Organization-defined eosinophilic disorders: 2017 update on diagnosis, risk stratification, and management. Am J Hematol. 2017;92:1243–59.
Reiter A, Gotlib J. Myeloid neoplasms with eosinophilia. Blood. 2017;129:704–14.
Crane MM, Chang CM, Kobayashi MG, Weller PF. Incidence of myeloproliferative hypereosinophilic syndrome in the United States and an estimate of all hypereosinophilic syndrome incidence. J Allergy Clin Immunol. 2010;126:179–81.
Dunphy CH. Chronic eosinophilic leukemia, not otherwise specified (CEL, NOS). Cancer Ther Rev. 2012;8:30–4.
Ogbogu PU, Bochner BS, Butterfield JH, Gleich GJ, Huss-Marp J, Kahn JE, et al. Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy. J Allergy Clin Immunol. 2009;124:1319–25. e1313.
Helbig G, Soja A, Bartkowska-Chrobok A, Kyrcz-Krzemien S. Chronic eosinophilic leukemia-not otherwise specified has a poor prognosis with unresponsiveness to conventional treatment and high risk of acute transformation. Am J Hematol. 2012;87:643–5.
Part VII: Hematologic Malignancies. In: Hematology (Seventh Edition), edited by Hoffman R, Benz EJ, Silberstein LE, Heslop HE, Weitz JI, et al. Elsevier, 2018, 763–1443 pp.
Bochner BS. Siglec-8 on human eosinophils and mast cells, and Siglec-F on murine eosinophils, are functionally related inhibitory receptors. Clin Exp Allergy. 2009;39:317–24.
Song DJ, Cho JY, Lee SY, Miller M, Rosenthal P, Soroosh P, et al. Anti-Siglec-F antibody reduces allergen-induced eosinophilic inflammation and airway remodeling. J Immunol. 2009;183:5333–41.
Song DJ, Cho JY, Miller M, Strangman W, Zhang M, Varki A, et al. Anti-Siglec-F antibody inhibits oral egg allergen induced intestinal eosinophilic inflammation in a mouse model. Clin Immunol. 2009;131:157–69.
Zimmermann N, McBride ML, Yamada Y, Hudson SA, Jones C, Cromie KD, et al. Siglec-F antibody administration to mice selectively reduces blood and tissue eosinophils. Allergy. 2008;63:1156–63.
Nutku E, Aizawa H, Hudson SA, Bochner BS. Ligation of Siglec-8: a selective mechanism for induction of human eosinophil apoptosis. Blood. 2003;101:5014–20.
Nutku E, Hudson SA, Bochner BS. Mechanism of Siglec-8-induced human eosinophil apoptosis: role of caspases and mitochondrial injury. Biochem Biophys Res Commun. 2005;336:918–24.
Varki A, Angata T. Siglecs–the major subfamily of I-type lectins. Glycobiology. 2006;16:1R–27R.
Nutku-Bilir E, Hudson SA, Bochner BS. Interleukin-5 priming of human eosinophils alters siglec-8 mediated apoptosis pathways. Am J Respir Cell Mol Biol. 2008;38:121–4.
Mao H, Kano G, Hudson SA, Brummet M, Zimmermann N, Zhu Z, et al. Mechanisms of Siglec-F-induced eosinophil apoptosis: a role for caspases but not for SHP-1, Src kinases, NADPH oxidase or reactive oxygen. PLoS One. 2013;8:e68143.
Camilleri AE, Nag S, Russo AR, Stiles KM, Crystal RG, Pagovich OE. Gene therapy for a murine model of eosinophilic esophagitis. Allergy. 2021;76:2740–52.
Mayginnes JP, Reed SE, Berg HG, Staley EM, Pintel DJ, Tullis GE. Quantitation of encapsidated recombinant adeno-associated virus DNA in crude cell lysates and tissue culture medium by quantitative, real-time PCR. J Virol Methods. 2006;137:193–204.
Wang F, Cui X, Wang M, Xiao W, Xu R. A reliable and feasible qPCR strategy for titrating AAV vectors. Med Sci Monit Basic Res. 2013;19:187–93.
Shultz LD, Ishikawa F, Greiner DL. Humanized mice in translational biomedical research. Nat Rev Immunol. 2007;7:118–30.
Shultz LD, Lyons BL, Burzenski LM, Gott B, Chen X, Chaleff S, et al. Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells. J Immunol. 2005;174:6477–89.
Pagovich OE, Camilleri AE, Nag S, Stiles KM, Crystal RG. AAV-mediated anti-eosinophil gene therapy for eosinophilic esophagitis. Mol Ther. 2020;28:90.
Pagovich OE, Russo AR, Whaley AS, Cronin S, Matsumura Y, Stiles KM, et al. Gene Therapy for chronic eosinophilic esophagitis. Mol Ther. 2018;26:161.
Davidoff AM, Ng CY, Zhou J, Spence Y, Nathwani AC. Sex significantly influences transduction of murine liver by recombinant adeno-associated viral vectors through an androgen-dependent pathway. Blood. 2003;102:480–8.
De BP, Heguy A, Hackett NR, Ferris B, Leopold PL, Lee J, et al. High levels of persistent expression of alpha1-antitrypsin mediated by the nonhuman primate serotype rh.10 adeno-associated virus despite preexisting immunity to common human adeno-associated viruses. Mol Ther. 2006;13:67–76.
Nietupski JB, Hurlbut GD, Ziegler RJ, Chu Q, Hodges BL, Ashe KM, et al. Systemic administration of AAV8-alpha-galactosidase A induces humoral tolerance in nonhuman primates despite low hepatic expression. Mol Ther. 2011;19:1999–2011.
Wu Z, Sun J, Zhang T, Yin C, Yin F, Van Dyke T, et al. Optimization of self-complementary AAV vectors for liver-directed expression results in sustained correction of hemophilia B at low vector dose. Mol Ther. 2008;16:280–9.
Dane AP, Wowro SJ, Cunningham SC, Alexander IE. Comparison of gene transfer to the murine liver following intraperitoneal and intraportal delivery of hepatotropic AAV pseudo-serotypes. Gene Ther. 2013;20:460–4.
Morsia E, Reichard K, Pardanani A, Tefferi A, Gangat N. WHO defined chronic eosinophilic leukemia, not otherwise specified (CEL, NOS): a contemporary series from the Mayo Clinic. Am J Hematol 2020;95:E172–E174.
Curtis C, Ogbogu P. Hypereosinophilic syndrome. Clin Rev Allergy Immunol. 2016;50:240–51.
Falchi L, Verstovsek S. Eosinophilia in hematologic disorders. Immunol Allergy Clin North Am. 2015;35:439–52.
Gotlib J. World Health Organization-defined eosinophilic disorders: 2011 update on diagnosis, risk stratification, and management. Am J Hematol. 2011;86:677–88.
Strati P, Cortes J, Faderl S, Kantarjian H, Verstovsek S. Long-term follow-up of patients with hypereosinophilic syndrome treated with Alemtuzumab, an anti-CD52 antibody. Clin Lymphoma Myeloma Leuk. 2013;13:287–91.
Hudson SA, Herrmann H, Du J, Cox P, Haddad el B, Butler B, et al. Developmental, malignancy-related, and cross-species analysis of eosinophil, mast cell, and basophil siglec-8 expression. J Clin Immunol. 2011;31:1045–53.
Klion AD 55 - Eosinophilia. In: Keystone JS, Freedman DO, Kozarsky PE, Connor BA, Nothdurft HD (eds). Travel Medicine (Third Edition). Elsevier Inc.: London, 2013, pp. 501–9.
Crocker PR, Paulson JC, Varki A. Siglecs and their roles in the immune system. Nat Rev Immunol. 2007;7:255–66.
Dellon ES, Peterson KA, Murray JA, Falk GW, Gonsalves N, Chehade M, et al. Anti-Siglec-8 antibody for eosinophilic gastritis and duodenitis. N Engl J Med. 2020;383:1624–34.
Siebenhaar F, Bonnekoh H, Hawro T, Hawro MO, Michaelis EG, Rasmussen HS, et al. Safety and efficacy data of AK002, an anti-siglec-8 monoclonal antibody, in patients with indolent systemic mastocytosis (ISM): Results from a first-in-human, open-label phase 1 study. 2019; https://www.allakos.com/file.cfm/59/docs/Levine_at_al_AAAAI_March_2020.pdf.
Allakos. Overview. 2020; https://www.allakos.com/.
Altrichter S, Staubach P, Pasha M, Rasmussen H, Singh B, Chang A, et al. Clincial activity of AK002, an anti-siglec-8 antibody, in multiple forms of uncontrolled chronic urticaria. Ann Allergy Asthma Immunol. 2019;123:S27–S28.
Levine T, Tauber J, Nguyen Q, Anesi S, Chang P, Berdy G, et al. Clinical activity of AK002, an anti-siglec-8 antibody, in severe allergic conjunctivitis and comorbid atopic diseases. Ann Allergy, Asthma Immunol. 2019;123:S17.
Butt NM, Lambert J, Ali S, Beer PA, Cross NC, Duncombe A, et al. Guideline for the investigation and management of eosinophilia. Br J Haematol. 2017;176:553–72.
Valent P, Klion AD, Horny HP, Roufosse F, Gotlib J, Weller PF, et al. Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. J Allergy Clin Immunol. 2012;130:607–12. e609.
Rosenberg JB, De BP, Hicks MJ, Janda KD, Kaminsky SM, Worgall S, et al. Suppression of nicotine-induced pathophysiology by an adenovirus hexon-based antinicotine vaccine. Hum Gene Ther. 2013;24:595–603.
Celestin J, Frieri M. Eosinophilic disorders in various diseases. Curr Allergy Asthma Rep. 2012;12:18–24.
Mejia R, Nutman TB. Evaluation and differential diagnosis of marked, persistent eosinophilia. Semin Hematol. 2012;49:149–59.
Hastie E, Samulski RJ. Recombinant adeno-associated virus vectors in the treatment of rare diseases. Expert Opin Orphan Drugs. 2015;3:675–89.
Mingozzi F, High KA. Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges. Nat Rev Genet. 2011;12:341–55.
Franklin W, Goetzl EJ. Total absence of eosinophils in a patient with an allergic disorder. Ann Intern Med. 1981;94:352–3.
Abidi K, Belayachi J, Derras Y, Khayari ME, Dendane T, Madani N, et al. Eosinopenia, an early marker of increased mortality in critically ill medical patients. Intensive Care Med. 2011;37:1136–42.
Terradas R, Grau S, Blanch J, Riu M, Saballs P, Castells X, et al. Eosinophil count and neutrophil-lymphocyte count ratio as prognostic markers in patients with bacteremia: a retrospective cohort study. PLoS ONE. 2012;7:e42860.
Gleich GJ, Klion AD, Lee JJ, Weller PF. The consequences of not having eosinophils. Allergy. 2013;68:829–35.
